Vanderbilt Institute Of Chemical Biology

The School of Medicine Basic Sciences and the Office of the Vice Provost for Research and Innovation launch the Innovation Ignition Fund. This pilot program offers up to $500,000 in funding and drug development mentorship from Vanderbilt scientists with expertise in translational research. Read More

Sean Davies and colleagues are exploring lipid aldehydes produced during oxidative stress and their contribution to HDL dysfunction and atherosclerosis. Read More

The Vanderbilt Institute of Chemical Biology (VICB) will hold a Founders’ Celebration mini-symposium on March 28 to acknowledge the contributions of its founders, Lawrence Marnett, PhD, and Ned Porter, PhD, and to celebrate 15-plus years of success as a trans-institutional scientific incubator. Read More

Vanderbilt researchers have discovered that curcumin — the active ingredient in the spice turmeric — needs to be metabolically activated to exert anti-inflammatory effects. Read More

Vanderbilt investigators have developed a new method for measuring oxidative stress in human tumors, which provides insight into cancer development. Read More

H. Alex Brown, Ph.D., the Bixler-Johnson-Mayes Professor in the Department of Pharmacology, has been named interim director of the Vanderbilt Institute of Chemical Biology (VICB). Read More

Vanderbilt researchers have discovered a novel model of evolution for factors that control gene expression. Read More

New structural details of the binding of the bacterium Streptococcus sanguinis to platelets may offer new therapeutics for life-threatening cardiovascular infections. Read More

Philip Low, Ph.D., director of the Purdue Center for Drug Discovery, will deliver the next Flexner Discovery Lecture on April 14. Read More

“Stay with science,” Nobel laureate Peter Agre, M.D., advised dozens of medical and graduate students who attended his lecture at Vanderbilt University Medical Center last week. “It will take you to fascinating places.” Read More

New findings add to the understanding of how the enzyme COX-2 works, which is critical to the development of COX-2-targeted anti-inflammatory drugs. Read More

A new imaging probe developed by Vanderbilt investigators enhances tumor visibility and has broad applications in diagnosing and monitoring patients with cancer. Read More

Jennifer Doudna, Ph.D., recipient of a 2015 Breakthrough Prize in Life Sciences, will deliver the next Flexner Discovery Lecture on Thursday, Jan. 8. Read More

A new compound that activates potassium channels could be used to treat disorders of glucose homeostasis. Read More

Vanderbilt researchers have identified a new signaling system that anthrax bacteria uses to infect its host. Read More

The antioxidant vitamin E prevented the buildup of toxic products in a model of a rare genetic disorder, suggesting new strategies for therapeutic development. Read More

Vanderbilt investigators used an in vivo screen in zebrafish to identify a potential new anti-cancer drug. Read More

Osteomyelitis, a debilitating bone infection most frequently caused by Staphylococcus aureus (“staph”) bacteria, is particularly challenging to treat. Read More

The Vanderbilt Institute of Chemical Biology (VICB) celebrated its 10th anniversary Tuesday with a daylong research symposium. Read More

Scott Hultgren, Ph.D., an expert on the interactions between bacteria and human hosts, will deliver the next Flexner Discovery Lecture on Thursday, March 7. Read More